RxDoctor Payments Data

Ashish Adi, MD

Pulmonary Disease · Fort Myers, FLNPI 1477500338

Payments from drug & device makers

$993in general payments, 2019–2025

Across 54 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$241
  • GSK$196
  • AstraZeneca$138
  • Sanofi$68
  • Baxter Healthcare$54
  • Actelion Pharmaceuticals US, Inc.$51
  • plus $245 from 9 others

What the payments were for

  • Food & beverage$993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$993 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$199,357
Medicare patients
673
Services billed
1,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate15$297,307
Trelegy ElliptaFluticasone/Umeclidin/Vilanter147$160,531
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$14,716
Breo ElliptaFluticasone/Vilanterol19$11,892
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$8,880
Spiriva RespimatTiotropium Bromide16$8,331
SymbicortBudesonide/Formoterol Fumarate31$8,277
DuleraMometasone/Formoterol18$8,082
Albuterol Sulfate HfaAlbuterol Sulfate109$2,988
BreynaBudesonide/Formoterol Fumarate13$1,864
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,834
Wixela InhubFluticasone Propion/Salmeterol19$888
Levalbuterol Tartrate HfaLevalbuterol Tartrate12$799
Prednisone35$235
Montelukast Sodium17$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$241$314,51944 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$196$187,138186 claims
AstraZenecaSymbicort$138$8,27731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →